

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Everolimus for preventing organ rejection in liver transplantation

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (everolimus) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • Afiya Trust • Black Health Agency • British Liver Trust • Equalities National Council • Muslim Council of Great Britain • Muslim Health Network • Liver4Life • South Asian Health Foundation • Specialised Healthcare Alliance • Transplant Support Network <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Geriatrics Society • British Liver Nurses Forum • British Society of Gastroenterology • British Transplantation Society • ESPRIT • NHS Blood and Transplant • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Accord Healthcare (mycophenolate mofetil, immediate-release tacrolimus) • Actavis UK (prednisolone, azathioprine, mycophenolate mofetil) • Arrow Generics (azathioprine, mycophenolate mofetil) • Aspen (azathioprine) • Astellas Pharma (immediate-release tacrolimus, prolonged-release tacrolimus) • Beacon Pharmaceuticals (methylprednisolone) • Dexcel Pharma (ciclosporin, immediate-release tacrolimus) • Dr Reddy's Laboratories (mycophenolate mofetil) • Intrapharm Laboratories (prednisolone) • LPC Medical (prednisolone) • Metwest Pharmaceuticals

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS North Lincolnshire CCG • Powys Teaching Health Board • Welsh Government 	<p>(prednisolone)</p> <ul style="list-style-type: none"> • Mylan UK (azathioprine, ciclosporin mycophenolate mofetil, immediate-release tacrolimus) • Novartis Pharmaceuticals (ciclosporin, mycophenolate sodium) • Pfizer (methylprednisolone) • Roche Products (mycophenolate mofetil) • Sandoz (azathioprine, mycophenolate mofetil, immediate-release tacrolimus) • Teva UK (azathioprine, ciclosporin, mycophenolate mofetil, prednisolone, immediate-release tacrolimus) • Wockhardt (mycophenolate mofetil, prednisolone) • Zentiva UK (mycophenolate mofetil, prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Renal Group • Foundation for Liver Research • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Peninsula Technology Assessment Group (PenTAG) • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations

from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.